Plains All American Pipeline (PAA)
(Delayed Data from NSDQ)
$17.37 USD
+0.36 (2.12%)
Updated May 17, 2024 04:00 PM ET
After-Market: $17.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PAA 17.37 +0.36(2.12%)
Will PAA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PAA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PAA
Is Plains All American Pipeline (PAA) a Great Value Stock Right Now?
Are Oils-Energy Stocks Lagging Marathon Oil (MRO) This Year?
PAA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Enterprise Products Partners (EPD) a Great Value Stock Right Now?
Plains All American (PAA) Q1 Earnings Top Estimates, Sales Lag
Plains All American Pipeline (PAA) Beats Stock Market Upswing: What Investors Need to Know
Other News for PAA
Let's Build A Bond Portfolio Together April 2024 - Rates Moving Up, Lock In Longer
PharmAust Limited Issues Investment Caution
PharmAust Gains FDA Orphan Drug Status for MND Treatment
Pharmaust Limited Welcomes New Director
PharmAust Director Sam Wright Steps Down